In previous work, we suggested that the increased MHC gene expression in tumour cells was the basis of the synergistic anti-tumour activity seen when zabadinostat is combined with immune checkpoint inhibitors10, reflecting enhanced CD4 and CD8 T lymphocytes in the tumour micro-environment10. Here, CD8A is linked to neoplasm.